Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-827104 in Pediatric EECSWS (Steamboat 2)
NCT05301894Phase 2Terminated
- Sponsor
- Neurocrine Biosciences
- Start
- Jun 2022
- Primary completion
- Jan 2025
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of NBI-827104 in Epileptic Encephalopathy With Continuous Spike-And-Wave During Slow Sleep (CSWS), sponsored by Neurocrine Biosciences. Primary endpoint: Number of Participants With Serious Treatment-emergent Adverse Events at 884 days. Started Jun 2022; status: terminated.
02
Drugs
NBI-827104
03
Conditions
Epileptic Encephalopathy With Continuous Spike-And-Wave During Slow Sleep (CSWS)
Beyond the preview
Go deeper on NCT05301894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05301894.